VIVA24: Late-Breaking Trials Highlight Advances in Vascular Intervention
The PROMISE II trial demonstrates sustained limb salvage and wound healing at 2 years using the LimFlow System for no-option CLTI patients.
VIVA24: Late-Breaking Trials Highlight Advances in Peripheral Artery Disease Treatment
The PROMISE II trial demonstrates sustained limb salvage and wound healing at two years using the LimFlow System for no-option CLTI patients.
VIVA24: Novel Therapies Show Promise in Vascular Disease Treatment
• The Esprit BTK scaffold demonstrated superior long-term outcomes in treating chronic limb-threatening ischemia compared to percutaneous transluminal angioplasty. • Shockwave Javelin Peripheral IVL catheter met efficacy and safety goals, significantly reducing stenosis in severely calcified lesions. • TCAR using the ENROUTE system proves safe and effective for carotid stenosis in standard-surgical-risk patients, with low stroke and cranial nerve injury rates.
Senseonics' Eversense 365 CGM System Receives FDA Clearance for One-Year Use
Senseonics and Ascensia Diabetes Care secured FDA clearance for Eversense 365, a next-generation continuous glucose monitoring (CGM) system, for adults with type 1 and type 2 diabetes.